Company developing breakthrough therapies for brain diseases has closed oversubscribed private placement to fund clinical trial planning and R & D.
Inability to penetrate the blood-brain barrier has been a roadblock to treat brain diseases. Reglagene has addressed this and paves the way in therapies offering brain cancer patients new hope.” — Richard Austin, Ph.D., MBAContinue reading
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Xcellerant Ventures welcomes Lenoss Medical into our Venture Fund I portfolio. Lenoss Medical is disrupting the treatment of spinal fractures with their OsteoPearl VBA System. This minimally invasive and cement-free technology delivers a fully biologic solution to stabilize spinal fractures and utilizes the natural healing properties of healthy bone.Continue reading
The University of Arizona Health Sciences announced December 12 it had selected McCarthy + SmithGroup to lead the design and construction of the Center for Advanced Molecular and Immunological Therapies, or CAMI, facility in downtown Phoenix.Continue reading
Acquisition Would Create a More Vertically Integrated Company, Bringing Direct Responsibility for Supply Chain and Seed Manufacturing along with Perspective Therapeutic’s Cesium-131 Brachytherapy BusinessContinue reading
WASHINGTON, D.C. – Today, AdvaMedDx submitted comments in response to the Food and Drug Administration’s Proposed Rule: Medical Devices; Laboratory Developed Tests. AdvaMedDx is a division of AdvaMed representing companies that develop in vitro diagnostic (IVD) tests.
TUCSON, Ariz., December 12, 2023 – Critical Path Institute (C-Path), a leader in advancing rare disease research, is pleased to announce a data collaboration with PicnicHealth, a patient-centered healthcare evidence generation company.Continue reading
TUCSON, Ariz., December 12, 2023 – C-Path (Critical Path Institute) is thrilled to announce a significant addition to its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®). Children’s Hospital of Orange County (CHOC) has generously contributed clinical trial data related to mucopolysaccharidosis (MPS), reinforcing the power of collaboration in advancing rare disease research.Continue reading
TUCSON, ARIZONA, DECEMBER 11, 2023 – Avery Therapeutics, Inc., a privately held, pre-clinical stage therapeutics company, developing therapeutics for diseases of aging, inflammation and fibrosis announces a publication in Nature Communications Biology, dated November 24, 2023. The article, titled “Biologically derived epicardial patch induces macrophage mediated pathophysiologic repair in chronically infarcted swine hearts,” demonstrates a novel approach in the treatment of chronic heart failure (CHF).Continue reading
World’s largest medical imaging companies join world’s largest medtech association
Continue reading